These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8310760)

  • 21. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
    Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
    J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.
    Whitehead SS; Bukreyev A; Teng MN; Firestone CY; St Claire M; Elkins WR; Collins PL; Murphy BR
    J Virol; 1999 Apr; 73(4):3438-42. PubMed ID: 10074199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.
    Connors M; Kulkarni AB; Collins PL; Firestone CY; Holmes KL; Morse HC; Murphy BR
    J Virol; 1992 Feb; 66(2):1277-81. PubMed ID: 1731105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics.
    Luongo C; Winter CC; Collins PL; Buchholz UJ
    J Virol; 2012 Oct; 86(19):10792-804. PubMed ID: 22837193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology.
    de Waal L; Wyatt LS; Yüksel S; van Amerongen G; Moss B; Niesters HG; Osterhaus AD; de Swart RL
    Vaccine; 2004 Feb; 22(8):923-6. PubMed ID: 15161069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate.
    Firestone CY; Whitehead SS; Collins PL; Murphy BR; Crowe JE
    Virology; 1996 Nov; 225(2):419-22. PubMed ID: 8918930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus.
    Olmsted RA; Buller RM; Collins PL; London WT; Beeler JA; Prince GA; Chanock RM; Murphy BR
    Vaccine; 1988 Dec; 6(6):519-24. PubMed ID: 3072795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells.
    Kulkarni AB; Morse HC; Bennink JR; Yewdell JW; Murphy BR
    J Virol; 1993 Jul; 67(7):4086-92. PubMed ID: 7685408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
    Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
    J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinants.
    Murphy BR; Collins PL; Lawrence L; Zubak J; Chanock RM; Prince GA
    J Gen Virol; 1989 Aug; 70 ( Pt 8)():2185-90. PubMed ID: 2671259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.
    Brock LG; Liu X; Liang B; Lingemann M; Liu X; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein.
    Bembridge GP; Garcia-Beato R; López JA; Melero JA; Taylor G
    J Immunol; 1998 Sep; 161(5):2473-80. PubMed ID: 9725246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
    Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
    Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunological properties of plaque purified strains of live attenuated respiratory syncytial virus (RSV) for human vaccine.
    Herlocher ML; Ewasyshyn M; Sambhara S; Gharaee-Kermani M; Cho D; Lai J; Klein M; Maassab HF
    Vaccine; 1999 Jan; 17(2):172-81. PubMed ID: 9987152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant measles viruses expressing respiratory syncytial virus proteins induced virus-specific CTL responses in cotton rats.
    Yamaji Y; Nakayama T
    Vaccine; 2014 Jul; 32(35):4529-4536. PubMed ID: 24951869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines.
    Swett-Tapia C; Bogaert L; de Jong P; van Hoek V; Schouten T; Damen I; Spek D; Wanningen P; Radošević K; Widjojoatmodjo MN; Zahn R; Custers J; Roy S
    J Gen Virol; 2016 Sep; 97(9):2117-2128. PubMed ID: 27311834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
    Durbin AP; Wyatt LS; Siew J; Moss B; Murphy BR
    Vaccine; 1998 Aug; 16(13):1324-30. PubMed ID: 9682397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates.
    Crowe JE; Bui PT; Firestone CY; Connors M; Elkins WR; Chanock RM; Murphy BR
    J Infect Dis; 1996 Apr; 173(4):829-39. PubMed ID: 8603960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cold-adapted mutant of parainfluenza virus type 3 is attenuated and protective in chimpanzees.
    Hall SL; Sarris CM; Tierney EL; London WT; Murphy BR
    J Infect Dis; 1993 Apr; 167(4):958-62. PubMed ID: 8383726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.